Loading...
Market
What will be the most significant challenge in the third set of teeth drug trials by end of 2025?
2
Resolution / Starting Odds
Safety concerns • 25%
Efficacy issues • 25%
Regulatory hurdles • 25%
Other • 25%
Reports and publications by the research team or scientific journals
Story
Japanese Researchers Test Drug to Regrow Third Set of Teeth, Targeting USAG-1 Protein in Clinical Trials
Dec 13, 2024, 01:30 PM
Japanese researchers are conducting clinical trials on a pioneering drug designed to stimulate the growth of a third set of teeth, which could provide a natural alternative to dentures and implants. The drug targets the USAG-1 protein and utilizes RNA technology to promote tooth regeneration. This development is significant as it challenges the long-held belief that humans and most mammals only grow two sets of teeth. Additionally, a study has identified 18 genomic regions linked to tooth shape and size, including a gene inherited from Neanderthals that influences these characteristics. The research is led by Katsu Takahashi at a medical research facility in Japan.
View original story
Similar markets
Significant tooth regrowth • 25%
Moderate tooth regrowth • 25%
Minimal tooth regrowth • 25%
No tooth regrowth • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Mild discomfort • 25%
Gum irritation • 25%
Severe pain • 25%
No significant side effects • 25%
Regulatory issues • 25%
Technical failures • 25%
Patient recruitment difficulties • 25%
No major challenges • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Supply chain issues • 25%
Regulatory hurdles • 25%
Vaccine hesitancy • 25%
Competition from other vaccines • 25%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Vaccine efficacy data • 25%
Adverse side effects • 25%
Trial participant demographics • 25%
Regulatory approval process • 25%